caa a22 4500 469073616 CHVBK 20180323132928.0 cr unu---uuuuu 170328e19921101xx s 000 0 eng 10.1007/BF01789021 doi (NATIONALLICENCE)springer-10.1007/BF01789021 Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer [Elektronische Daten] [Elaine Derbyshire, Rolf Stahel, Edward Wawrzynczak] Summary: The cytotoxic properties of a ricin A chain immunotoxin made with the mouse monoclonal antibody SWA20, recognising a family of sialoglycoprotein antigens selectively expressed by human small-cell lung cancer (SCLC), were examined using a panel of tumour cell lines in tissue culture. SWA20—ricin-A-chain was selectively toxic to the SW2, NCI-H69 and GLC-8 SCLC cell lines, inhibiting the incorporation of [3H]leucine by 50% at a concentration of 0.2-2 nM, but had no selective activity against the NCI-H23 and NCI-H125 lung adenocarcinoma or the control CEM T-lymphoblastoid cell lines. The SWA20 immunotoxin intoxicated the SW2 cell line rapidly, inhibiting [3H]leucine incorporation by 50% within 2 h compared with 0.5 h for ricin. Analysis of the effects of SWA20—ricin-A-chain on the growth of SW2 cells using a limiting-dilution clonogenic assay revealed that the immunotoxin could eliminate 95% of clonogenic malignant cells. Although SWA20—ricin-A-chain was found to be rapidly active against the majority of tumour cells, its action was limited by the presence of insensitive cells expressing low levels of the target antigen. Springer-Verlag, 1992 Ricin A chain nationallicence Immunotoxin nationallicence Small-cell lung cancer nationallicence Cluster-5A antigen nationallicence Derbyshire Elaine Drug Targeting Laboratory, Section of Immunology, Institute of Cancer Research, SM2 5NG, Sutton, Surrey, UK aut Stahel Rolf Division of Oncology, University Hospital, CH-8091, Zurich, Switzerland aut Wawrzynczak Edward Drug Targeting Laboratory, Section of Immunology, Institute of Cancer Research, SM2 5NG, Sutton, Surrey, UK aut Cancer Immunology, Immunotherapy Springer-Verlag 35/6(1992-11-01), 417-420 0340-7004 35:6<417 1992 35 262 https://doi.org/10.1007/BF01789021 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01789021 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Derbyshire Elaine Drug Targeting Laboratory, Section of Immunology, Institute of Cancer Research, SM2 5NG, Sutton, Surrey, UK aut NATIONALLICENCE 700 1- Stahel Rolf Division of Oncology, University Hospital, CH-8091, Zurich, Switzerland aut NATIONALLICENCE 700 1- Wawrzynczak Edward Drug Targeting Laboratory, Section of Immunology, Institute of Cancer Research, SM2 5NG, Sutton, Surrey, UK aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/6(1992-11-01), 417-420 0340-7004 35:6<417 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer